The debate supports carrying forward GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD only if a proximal endpoint changes before the late outcome. The decisive validation path is: resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
2 citations0 with PMIDValidation: 0%1 supporting / 1 opposing
✓For(1)
No supporting evidence
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
GFAP is a state marker more than a specific interv…
Opposing
CLIN
AD-MASTER-PLAN-…
-
-
-
-
-
Legacy Card View — expandable citation cards
✓ Supporting Evidence
1
Preregistered claim: GFAP-positive reactive astrocytes mediate regional vulnerability through dysfunction of m…▼
Preregistered claim: GFAP-positive reactive astrocytes mediate regional vulnerability through dysfunction of metabolic support, driving AD progression in affected regions
AD-MASTER-PLAN-GFAP-20260428030756
✗ Opposing Evidence
1
GFAP is a state marker more than a specific intervention point, and reactive astrocytes can be protective or h…▼
GFAP is a state marker more than a specific intervention point, and reactive astrocytes can be protective or harmful
AD-MASTER-PLAN-GFAP-20260428030756
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-28 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Theorist position for analysis AD-MASTER-PLAN-GFAP-20260428030756: AD Master Plan preregistration: GFAP
Context: Preregistered claim: GFAP-positive reactive astrocytes mediate regional vulnerability through dysfunction of metabolic support, driving AD progression in affected regions
Primary claim: GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this AD master-plan p
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic critique for analysis AD-MASTER-PLAN-GFAP-20260428030756: AD Master Plan preregistration: GFAP
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: GFAP is a state marker more than a specific intervention point, and reactive astrocytes can be protective or harmful.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across GFA
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain expert assessment for analysis AD-MASTER-PLAN-GFAP-20260428030756: AD Master Plan preregistration: GFAP
The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.
Feasibility is
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD requires proximal validation", "description": "The debate supports carrying forward GFAP-positive reactive astrocyte states as mediators of regional metabolic vulnerability in AD only if a proximal endpoint changes before the late outcome. The decisive validation path is: resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems.", "target_gene": "GFAP", "dim
Price History
No price history recorded yet
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0
Clinical Trials (0)
No clinical trials data available
📚 Cited Papers (0)
No linked papers yet
📅 Citation Freshness Audit
Freshness score = exp(-age×ln2/5): halves every 5 years.
Green >0.6,
Amber 0.3–0.6,
Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.